Galmed Pharmaceuticals Ltd. EOCN
Annual
Quarterly
No annual revenue total was found in GALMED PHARMACEUTICALS LTD.'s SEC filings.
Galmed Pharmaceuticals Ltd. (EOCN) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-10.31M
-37.1% vs prior year
Operating cash flow
$-6.32M
-7.4% vs prior year
Free cash flow
$-18.50M
+43.8% vs prior year
EPS
$2.39
-70.4% vs prior year
Dividend per share
None
Shares outstanding
6.58M
+297.8% vs prior year
Net cash
$11.84M
FY 2024
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EOCN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Ramat Gan, Israel
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1595353
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Net income | -$10.3M | -$7.5M | -$6.9M | -$17.9M | -$32.5M |
| Diluted EPS | $2.39 | $8.08 | $30.00 | — | — |
| Operating cash flow | -$6.3M | -$5.9M | -$6.1M | -$18.5M | -$32.9M |
| Free cash flow | — | — | — | -$18.5M | -$32.9M |
| Total assets | $18.6M | $18.5M | $16.6M | $16.6M | $36.6M |
| Stockholders' equity | $15.8M | $16.3M | $13.9M | $13.4M | $30.5M |
| Cash and investments | $11.0M | $11.8M | $10.4M | $15.3M | $34.8M |
| Total debt | — | $0 | $41,000 | $216,000 | $435,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 9, 2026 | Sep 9, 2026 |
| 6-K | Current report (foreign issuer) | Sep 8, 2026 | Sep 8, 2026 |
| 6-K | Current report (foreign issuer) | Sep 3, 2026 | Sep 3, 2026 |
| 6-K | Current report (foreign issuer) | Sep 2, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Sep 2, 2026 | Sep 2, 2026 |
| 6-K/A | Filing | Aug 19, 2026 | Jul 22, 2026 |
All 381 Galmed Pharmaceuticals Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.